Die Daten von Jinshi am 28. Dezember zeigen, dass am 27. Dezember Ortszeit das Unternehmen Daiichi Sankyo bekannt gab, dass das mit AstraZeneca gemeinsam entwickelte zielgerichtete TROP2-Antikörper-Wirkstoff-Konjugat (ADC) DATROWAY® (trastuzumab deruxtecan) in Japan zur Behandlung von nicht operablen oder rezidivierenden Brustkrebspatienten im Erwachsenenalter mit hormonrezeptorpositivem (HR) und humanem epidermalem Wachstumsfaktorrezeptor 2 (HER2)-negativem (IHC 0, IHC 1+ oder IHC 2+/ISH-) Zustand nach einer Chemotherapie zugelassen wurde.
Disclaimer: The information on this page may come from third parties and does not represent the views or opinions of Gate. The content displayed on this page is for reference only and does not constitute any financial, investment, or legal advice. Gate does not guarantee the accuracy or completeness of the information and shall not be liable for any losses arising from the use of this information. Virtual asset investments carry high risks and are subject to significant price volatility. You may lose all of your invested principal. Please fully understand the relevant risks and make prudent decisions based on your own financial situation and risk tolerance. For details, please refer to
Disclaimer.